Allena Pharmaceuticals, Inc. Investing cash flow

Investing cash flow of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Investing cash flow growth rates and interactive chart.


Highlights and Quick Summary

  • Investing cash flow for the quarter ending December 31, 2021 was $-25 Thousand (a -86.49% decrease compared to previous quarter)
  • Year-over-year quarterly Investing cash flow decreased by -94.08%
  • Annual Investing cash flow for 2021 was $-667 Thousand (a 5.54% increase from previous year)
  • Annual Investing cash flow for 2020 was $-632 Thousand (a 418.03% increase from previous year)
  • Annual Investing cash flow for 2019 was $-122 Thousand (a -61.64% decrease from previous year)
  • Twelve month Investing cash flow ending December 31, 2021 was $-667 Thousand (a -47.65% decrease compared to previous quarter)
  • Twelve month trailing Investing cash flow decreased by -36.72% year-over-year
Trailing Investing cash flow for the last four month:
31 Dec '21 30 Sep '21 30 Jun '21 31 Mar '21
$-667 Thousand $-1.27 Million $-1.09 Million $-1.05 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Investing cash flow of Allena Pharmaceuticals, Inc.

Most recent Investing cash flowof ALNA including historical data for past 10 years.

Interactive Chart of Investing cash flow of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Investing cash flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-0.03 $-0.19 $-0.04 $-0.42 $-0.67
2020 $-0.63 $0.0 $0.0 $0.0 $-0.63
2019 $0.0 $-0.02 $-0.02 $-0.08 $-0.12
2018 $-0.16 $-0.04 $-0.08 $-0.03 $-0.32
2017 $-0.0 $3.25 $10.87 $9.3 $23.42
2016 $5.99 $-29.75 $-23.76
2015 $0.01 $0.01

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.